HHS Secretary Announces Expansion of Reimbursement for CDC-Recognized Diabetes Prevention Programs like Omada Health
San Francisco, CA (March 23, 2016) – Acknowledging diabetes as one of the most pressing issues facing the American healthcare system, U.S. Department of Health and Human Services Secretary Sylvia M. Burwell announced today that Medicare will begin reimbursing CDC-recognized providers like Omada Health for administering the Diabetes Prevention Program (DPP) to eligible beneficiaries. On the sixth anniversary of the Affordable Care Act, Secretary Burwell’s announcement underscores Medicare’s commitment to value-based care by extending the agency’s investment in chronic disease prevention.
Today, more than half of all Americans over the age of 65 have prediabetes, and fewer than one in ten are aware they have the condition. Without intervention, one third of those with prediabetes will likely progress to type 2 diabetes in the next three years. In 2014, Medicare spent more than $15,700 per beneficiary with diabetes, and according to the Diabetes Care Project, one of every three dollars spent by Medicare goes to treating individuals with the condition.
“Today’s commitment by HHS quite literally extends a lifeline to 22 million American seniors with prediabetes,” said Omada Health co-founder and CEO Sean Duffy. “We feel fortunate to have the opportunity to work with CMS, Medicare Advantage plans, health systems, and physicians across the country to make a profound impact in these individuals’ lives. By elevating evidence-based diabetes prevention as the reimbursed standard of care, Secretary Burwell has acknowledged the urgency of addressing what has become a national epidemic. We look forward to continuing to provide data, evidence, and implementation insight to the team at HHS to ensure that the diabetes prevention benefit is implemented effectively, and reaches as many eligible beneficiaries as possible.”
Read More: https://omadahealth.com/news/medicare-will-cover-diabetes-prevention-program-for-at-risk-seniors
Via: Omada Health
Monteris Medical has opened its new headquarters facility in Plymouth.
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
REDWOOD CITY, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed's investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck's anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA®). The combination of these agents may act as a double blockade for cancer-induced immune suppression with potential application to a number of solid tumor cancers.
Silk Road Medical Announces CE Mark Approval and First Patients Treated with the Next Generation ENROUTE® Transcarotid Neuroprotection System
Via: PR Newswire
SUNNYVALE, Calif., March 15, 2016 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced CE Mark approval for its next generation ENROUTE Transcarotid Neuroprotection System (NPS). The ENROUTE NPS remains the only device specifically designed and indicated for TransCarotid Artery Revascularization (TCAR), a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
Remedy Pharmaceuticals Appoints Thomas MacAllister as Vice President of Research and Development and General Counsel
Via: Business Wire
NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held, Phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company appointed Thomas MacAllister as Vice President of Research and Development, and General Counsel.
OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2015 Financial Results and 2016 Guidance
Projects Two Years' Cash Runway — without Partner-related Milestones/Opt-ins
Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA On A Novel Drug Treatment For CNS-Related Edema
NEW YORK, New York, March 4, 2016 — Remedy Pharmaceuticals, a privately-held, pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which took place on March 2, 2016.
Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA™ Presented at International Stroke Conference
Via: Yahoo! Finance
A more than three-fold reduction in mortality in patients ≤70 years old; adjudicated neurological mortality reduced more than three-fold, and death from edema reduced 10-fold.
Higher Doses of Tarextumab Appear to Correlate with Improved Progression-free and Overall Survival
Via: Clinton Foundation
By Chelsea Clinton, Vice Chair of the Clinton Foundation